Receptor, Fibroblast Growth Factor, Type 3
"Receptor, Fibroblast Growth Factor, Type 3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A fibroblast growth factor receptor that regulates CHONDROCYTE growth and CELL DIFFERENTIATION. Mutations in the gene for fibroblast growth factor receptor 3 have been associated with ACHONDROPLASIA; THANATOPHORIC DYSPLASIA and NEOPLASTIC CELL TRANSFORMATION.
MeSH Number(s)
D08.811.913.696.620.682.725.400.179
D12.776.543.750.060.442
D12.776.543.750.750.400.370.875
D12.776.624.664.700.792
Below are MeSH descriptors whose meaning is more general than "Receptor, Fibroblast Growth Factor, Type 3".
- Chemicals and Drugs [D]
- Enzymes and Coenzymes [D08]
- Enzymes [D08.811]
- Transferases [D08.811.913]
- Phosphotransferases [D08.811.913.696]
- Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
- Protein Kinases [D08.811.913.696.620.682]
- Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
- Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
- Receptor, Fibroblast Growth Factor, Type 3 [D08.811.913.696.620.682.725.400.179]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptor Protein-Tyrosine Kinases [D12.776.543.750.060]
- Receptor, Fibroblast Growth Factor, Type 3 [D12.776.543.750.060.442]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Growth Factor [D12.776.543.750.750.400]
- Receptors, Fibroblast Growth Factor [D12.776.543.750.750.400.370]
- Receptor, Fibroblast Growth Factor, Type 3 [D12.776.543.750.750.400.370.875]
- Neoplasm Proteins [D12.776.624]
- Oncogene Proteins [D12.776.624.664]
- Proto-Oncogene Proteins [D12.776.624.664.700]
- Receptor, Fibroblast Growth Factor, Type 3 [D12.776.624.664.700.792]
Below are MeSH descriptors whose meaning is more specific than "Receptor, Fibroblast Growth Factor, Type 3".
This graph shows the total number of publications written about "Receptor, Fibroblast Growth Factor, Type 3" by people in Harvard Catalyst Profiles by year, and whether "Receptor, Fibroblast Growth Factor, Type 3" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 2000 | 0 | 2 | 2 |
| 2004 | 0 | 3 | 3 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 2 | 0 | 2 |
| 2008 | 1 | 1 | 2 |
| 2009 | 1 | 1 | 2 |
| 2010 | 1 | 1 | 2 |
| 2011 | 2 | 2 | 4 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 1 | 2 |
| 2014 | 8 | 2 | 10 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 3 | 4 |
| 2017 | 4 | 3 | 7 |
| 2018 | 1 | 3 | 4 |
| 2019 | 3 | 5 | 8 |
| 2020 | 1 | 1 | 2 |
Below are the most recent publications written about "Receptor, Fibroblast Growth Factor, Type 3" by people in Profiles.
-
LncRNA KCNQ1OT1 accelerates fracture healing via modulating miR-701-3p/FGFR3 axis. FASEB J. 2020 04; 34(4):5208-5222.
-
Molecular basis for receptor tyrosine kinase A-loop tyrosine transphosphorylation. Nat Chem Biol. 2020 03; 16(3):267-277.
-
Erdafitinib for the treatment of metastatic bladder cancer. Expert Rev Clin Pharmacol. 2020 Jan; 13(1):1-6.
-
Current Diagnosis and Treatment of Painful Small Fiber Neuropathy. Curr Neurol Neurosci Rep. 2019 11 26; 19(12):103.
-
Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer. Trends Cancer. 2019 11; 5(11):677-692.
-
Genetic basis of rotator cuff injury: a systematic review. BMC Med Genet. 2019 09 02; 20(1):149.
-
Expression of miR-100 and miR-138 as prognostic biomarkers in non-muscle-invasive bladder cancer. APMIS. 2019 Aug; 127(8):545-553.
-
Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nat Commun. 2019 07 05; 10(1):2977.
-
A Simple Immunohistochemical Panel Could Predict and Correlate to Clinicopathologic and Molecular Subgroups of Urinary Bladder Urothelial Carcinoma. Clin Genitourin Cancer. 2019 06; 17(3):e712-e719.
-
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations. Clin Cancer Res. 2019 05 01; 25(9):2699-2707.